Communications Biology,
Journal Year:
2025,
Volume and Issue:
8(1)
Published: April 9, 2025
Cancer
cachexia
is
a
cancer-associated
disease
characterized
by
gradual
body
weight
loss
due
to
pathologic
muscle
and
fat
loss,
but
effective
treatments
are
still
lacking.
Here,
we
investigate
the
possible
effect
of
vanillic
acid
(VA),
known
for
its
antioxidant,
anti-inflammatory,
anti-obesity
effects,
on
mitochondria-mediated
improvement
cancer
cachexia.
We
utilized
cachexia-like
models
using
CT26
colon
dexamethasone.
VA
improved
representative
parameters
including
increased
serum
intereukin-6
levels.
also
attenuated
in
tibialis
anterior
gastrocnemius
muscles,
inhibited
proteolytic
markers
RING-finger
protein-1
(MURF1)
atrophy
F-box
(MAFbx)
mitochondrial
function
through
alteration
sirtuins
3
(SIRT3)
mitofusin
1
(MFN1).
Importantly,
silencing
SIRT3
gene
abolished
VA,
indicating
that
important
mechanism
action
VA.
Overall,
suggest
as
novel
therapeutic
agent
can
fundamentally
treat
recover
patients.
Pharmaceuticals,
Journal Year:
2022,
Volume and Issue:
15(9), P. 1156 - 1156
Published: Sept. 16, 2022
Atriplex
halimus
L.,
also
known
as
Mediterranean
saltbush,
and
locally
"Lgtef",
an
halophytic
shrub,
is
used
extensively
to
treat
a
wide
variety
of
ailments
in
Morocco.
The
present
study
was
undertaken
determine
the
antioxidant
activity
cytotoxicity
ethanolic
extract
A.
leaves
(AHEE).
We
first
determined
phytochemical
composition
AHEE
using
liquid
chromatography
(LC)-tandem
mass
spectrometry
(MS/MS)
technique.
evaluated
different
methods
including
DPPH
scavenging
capacity,
β-carotene
bleaching
assay,
ABTS
scavenging,
iron
chelation,
total
capacity
assays.
Cytotoxicity
investigated
against
human
cancer
breast
cells
lines
MCF-7
MDA-MB-231.
results
showed
that
components
are
composed
phenolic
acids
flavonoids.
test
strong
for
leaf
(IC50
0.36
±
0.05
mg/mL)
comparison
ascorbic
acid
0.19
0.02
mg/mL).
IC50
2.91
0.14
mg/mL.
values
ABTS,
TAC
tests
were
44.10
2.92
TE
µmol/mL,
27.40
1.46
mg/mL,
124
1.27
µg
AAE/mg,
respectively.
In
vitro,
AHE
significant
inhibitory
all
tested
tumor
cell
lines,
inhibition
found
dose-dependent
manner.
Furthermore,
computational
techniques
such
molecular
docking
ADMET
analysis
this
work.
Moreover,
physicochemical
parameters
related
compounds'
pharmacokinetic
indicators
evaluated,
absorption,
distribution,
metabolism,
excretion,
toxicity
prediction
(Pro-Tox
II).
American Society of Clinical Oncology Educational Book,
Journal Year:
2023,
Volume and Issue:
43
Published: June 1, 2023
Significant
progress
in
our
understanding
of
cancer
cachexia
has
occurred
recent
years.
Despite
these
advances,
no
pharmacologic
agent
achieved
US
Food
and
Drug
Administration
approval
for
this
common
highly
morbid
syndrome.
Fortunately,
improved
the
molecular
basis
led
to
novel
targeted
approaches
that
are
varying
stages
drug
development.
This
article
reviews
two
major
thematic
areas
driving
strategies,
including
those
targeting
signal
mediators
at
level
CNS
skeletal
muscle.
Additionally,
strategies
being
tested
combination
with
nutrients,
nutrition
therapy,
exercise
treat
cachexia.
To
end,
we
highlight
recently
published
ongoing
trials
evaluating
therapies
specific
areas.
Cancers,
Journal Year:
2021,
Volume and Issue:
13(14), P. 3615 - 3615
Published: July 19, 2021
Cancer
cachexia
is
a
debilitating
multi-factorial
wasting
syndrome
characterised
by
severe
skeletal
muscle
and
dysfunction
(i.e.,
myopathy).
In
the
oncology
setting,
arises
from
synergistic
insults
both
cancer–host
interactions
chemotherapy-related
toxicity.
The
majority
of
studies
have
surrounded
interaction
side
cancer
cachexia,
often
overlooking
capability
chemotherapy
to
induce
cachectic
myopathy.
Accumulating
evidence
in
experimental
models
suggests
that
some
chemotherapeutic
agents
rapidly
myopathy,
although
underlying
mechanisms
responsible
vary
between
agents.
Importantly,
we
highlight
capacity
specific
as
not
all
chemotherapies
been
evaluated
for
cachexia-inducing
properties—alone
or
clinically
compatible
regimens.
Furthermore,
discuss
surrounding
therapeutic
strategies
chemotherapy-induced
models,
with
particular
focus
on
exercise
interventions
adjuvant
candidates
targeted
at
mitochondria.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 905 - 905
Published: March 15, 2023
Paraneoplastic
conditions
such
as
cancer
cachexia
are
often
exacerbated
by
chemotherapy,
which
affects
the
patient’s
quality
of
life
well
response
to
therapy.
The
aim
this
narrative
review
was
overview
body-composition-related
changes
and
molecular
effects
different
chemotherapy
agents
used
in
treatment
on
skeletal-muscle
remodeling.
A
literature
search
performed
using
Web
Science,
Scopus,
Science
Direct
databases
a
total
77
papers
retrieved.
In
general,
survey
showed
that
induced
skeletal
muscle
have
been
studied
mainly
animal
models
mostly
non-tumor-bearing
rodents,
whereas
clinical
studies
essentially
assessed
body
composition
computerized
tomography.
Data
from
preclinical
modulates
several
pathways
muscle,
including
ubiquitin–proteasome
pathway,
autophagy,
IGF-1/PI3K/Akt/mTOR,
IL-6/JAK/STAT,
NF-κB
pathway;
however,
newest
underexplored.
conclusion,
exacerbates
wasting
patients;
incomplete
characterization
chemotherapy-related
makes
development
new
preventive
anti-wasting
strategies
difficult.
Therefore,
further
investigation
mechanisms
necessary.
